hotspot -WSS

hotspot

author：entertainment 2025-10-03 00:38:56 - browse：7913

Duchenne muscular dystrophy is a devastating disease and, until very recently, was one without much hope. When Hawken Miller was diagnosed at age 5, the physician told his parents to enjoy the time they had with him, as there wouldn’t be much. Over 20 years later, Miller is a journalist and content strategist for CureDuchenne, an organization started by his mother when he was diagnosed, and new treatment is on the horizon.

Last month, the FDA approved a new gene therapy from Sarepta Therapeutics that will provide hope for many patients and families. The new drug, however, has its limitations — it’s only approved for children age 4-5, for example. Miller joined the podcast to discuss how this drug may change lives, what more needs to happen, and what his personal experience has been living with Duchenne.

“For the older boys, we’re running up against the clock a little bit with what we’re able to do and what we’re not able to do,” Miller said. “And if we’re able to try anything that could possibly help, I think most people would like the opportunity to do that.”

The conversation is based off his recent First Opinion, “The FDA’s approval of a new gene therapy for Duchenne muscular dystrophy won’t help me — but it gives me hope.”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Novavax promises a turnaround & Lilly roils the obesity market

WSS

Why getting cancer drugs just got harder for rural patients

BioMarin wins approval for gene therapy to treat hemophilia A

Cancer drug shortages should be causing more outrage

FDA does about

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Congress gives doctors Medicare pay bump

knowledge

hotspot

hotspot

The high cost of giving birth even with insurance

Biotech companies concerned about China biosecurity crackdown

In age of alternative facts, a scholarly course on calling out crap

FDA does about

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Medicare details structure of new drug price negotiation program

In age of alternative facts, a scholarly course on calling out crap

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

FDA approval of Sarepta Duchenne genetic therapy gives me hope

RSV vaccines may be linked to small increased risk of developing GBS

explore

RSV vaccines may be linked to small increased risk of developing GBS

FDA does about

House looks to weaken Medicare negotiation

Sports medicine is finally prioritizing gender equality

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

Obesity now affects over 1 billion people worldwide, study finds

entertainment

hotspot

Wikipedia

explore